The combined administration of cardamonin and PM triggered an increase in the level of phospho-MLKL in both breast cancer lines compared not only to the corresponding control but also to the parallel cultures that had been treated with the variant alone (Figure 2G,H). This evidence concerns the gene MLKL and breast carcinoma.